- Home
- STRW vs MOLN Comparison
STRW vs MOLN Comparison
Compare STRW & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STRW | MOLN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 157.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | STRW | MOLN |
|---|---|---|
| Price | $13.18 | $4.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $12.72 | $4.00 |
| AVG Volume (30 Days) | ★ 33.5K | 6.4K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ 19.41 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $145,392,000.00 | N/A |
| Revenue This Year | $35.42 | N/A |
| Revenue Next Year | $7.19 | $1,000.00 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | ★ 29.76 | N/A |
| 52 Week Low | $8.70 | $3.36 |
| 52 Week High | $13.77 | $5.99 |
Technical Indicators
Market Signals| Indicator | STRW | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 61.70 |
| Support Level | $12.30 | $3.99 |
| Resistance Level | $13.77 | $4.61 |
| Average True Range (ATR) | 0.46 | 0.16 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 73.97 | 84.92 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.